Skye Bioscience Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	5.88	68.42	1.26	1.24	8.98
Short-Term Investments	19.85	-	-	-	-
Cash & Short-Term Investments	25.74	68.42	1.26	1.24	8.98
Cash Growth	-62.38%	5345.15%	0.96%	-86.15%	263.77%
Other Current Assets	1.36	2.41	10.39	7.7	0.63
Total Current Assets	27.09	70.83	11.65	8.94	9.61
Net Property, Plant & Equipment	1.17	1.88	0.28	0.16	0.23
Other Long-Term Assets	0.05	0.05	0.01	0.01	0.01
Total Assets	28.31	72.76	11.94	9.11	9.86
Accounts Payable	2.03	0.57	0.96	1.79	0.9
Accrued Expenses	1.27	1.11	1.25	0.67	0.52
Short-Term Debt	-	-	4.37	1.85	1.97
Current Portion of Leases	0.19	0.18	0.07	0.08	0.08
Other Current Liabilities	4.71	2.47	7.25	7.72	0.44
Total Current Liabilities	8.21	4.34	13.9	12.12	3.91
Long-Term Leases	0.08	0.27	0.17	-	0.08
Total Long-Term Liabilities	0.08	0.27	0.17	-	0.08
Total Liabilities	8.29	4.61	14.07	12.12	3.99
Common Stock	0.03	0.03	0.01	0	0.48
Additional Paid-in Capital	206.87	199.07	102.24	63.73	52.64
Retained Earnings	-	-130.95	-104.38	-66.74	-47.26
Shareholders' Equity	206.9	68.15	-2.13	-3.01	5.86
Total Liabilities & Equity	28.31	72.76	11.94	9.11	9.86
Total Debt	0.27	0.46	4.62	1.93	2.14
Net Cash (Debt)	25.46	67.96	-3.36	-0.68	6.85
Net Cash Growth	-62.53%	-	-	-	604.71%
Net Cash Per Share	0.64	1.86	-0.48	-0.31	4.21
Book Value	206.9	68.15	-2.13	-3.01	5.86
Book Value Per Share	5.22	1.87	-0.30	-1.35	3.61
Tangible Book Value	206.9	68.15	-2.13	-3.01	5.86
Tangible Book Value Per Share	5.22	1.87	-0.30	-1.35	3.61

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q